Trial Profile

Ofatumumab Versus Rituximab Salvage Chemoimmunotherapy Followed by Autologous Stem Cell Transplant (ASCT) in Relapsed or Refractory Diffuse Large B Cell Lymphoma (DLBCL)

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 31 Aug 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ofatumumab (Primary) ; Cisplatin; Cytarabine; Dexamethasone; Dexamethasone; Rituximab
Indications Diffuse large B cell lymphoma; Follicular lymphoma
Focus Registrational; Therapeutic Use
Acronyms ORCHARRD
Sponsors GlaxoSmithKline; GSK

Most Recent Events

05 Jun 2019 This trial has been discontinued in UK, according to European Clinical Trials Database.
28 Dec 2016 Results assessing difference in efficacy of O-DHAP and R-DHAP published in the Journal of Clinical Oncology
02 Mar 2015 Status changed from active, no longer recruiting to completed, according to ClinicalTrials.gov record.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com